Aerie Pharmaceuticals Names Vicente Anido, Jr. as Chairman of the Board, and David Epstein as Chairman of Aerie’s Scientific

  Aerie Pharmaceuticals Names Vicente Anido, Jr. as Chairman of the Board, and
  David Epstein as Chairman of Aerie’s Scientific Advisory Board

Business Wire

BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. -- April 4, 2013

Aerie Pharmaceuticals, Inc. announced today that Vicente Anido, Jr., Ph.D.,
was named Chairman of Aerie’s Board of Directors. Dr. Anido is a
well-respected ophthalmology industry veteran and leader, who most recently
served as President and Chief Executive Officer of ISTA Pharmaceuticals prior
to its acquisition by Bausch + Lomb. Aerie also announced that David Epstein,
M.D., Chairman, Department of Ophthalmology, Duke University School of
Medicine, and Aerie Co-Founder, has been named as Chairman of the Company’s
Scientific Advisory Board.

“On behalf of the Aerie Board and Aerie’s employees, we welcome Vince Anido as
our new Chairman, and we look forward to his contributions to Aerie’s
continuing success in advancing our novel glaucoma product candidates,” said
Thomas van Haarlem, M.D., Aerie’s President and Chief Executive Officer.

From 2001 to 2012, Dr. Anido was President, Chief Executive Officer and a
Director of ISTA Pharmaceuticals. Prior to this, Dr. Anido was general partner
of Windamere Venture partners, served as President and CEO of CombiChem, Inc.,
a biotechnology company, and was President of the Americas Region of Allergan,
a specialty pharmaceutical company focusing on ophthalmology, dermatology and
neuromuscular indications. Dr. Anido currently serves on the Board of
Directors of QLT, Inc. and Depomed, Inc., both of which are NASDAQ-listed
pharmaceutical companies. He received a B.S. in Pharmacy and an M.S. in
Pharmacy Administration from West Virginia University, and a Ph.D. in Pharmacy
Administration from the University of Missouri-Kansas City.

Dr. Epstein has spent many years addressing the core problem in glaucoma –
abnormalities of the trabecular meshwork. He has been honored by a long list
of awards throughout his career, and has held several leadership positions in
ophthalmology associations, including President of the Association of
University Professors of Ophthalmology (AUPO) from 2011 to 2012, President of
the Chandler-Grant Glaucoma Society (2004 - 2005), and President of the
Association for Research in Vision and Ophthalmology (ARVO) (1992 – 1993),
which will be recognizing Dr. Epstein with the Mildred Weisenfeld Award for
Excellence in Ophthalmology, to be presented at the 2013 ARVO Annual Meeting
in May.

Dr. van Haarlem stated, “David has served as a long-time Aerie Board member
and has been a highly valued member of the team since he participated in the
Company’s founding in 2005. We are very pleased to have him take this
important leadership position heading our Scientific Advisory Board.”

About Aerie Pharmaceuticals

Aerie Pharmaceuticals is a privately held pharmaceutical company in late Phase
2 dedicated to the discovery and development of novel small-molecule
treatments for glaucoma. Aerie’s internal research and development engine has
generated an innovative glaucoma pipeline of three proprietary products, all
of which are well tolerated, high efficacy, once-daily eye drop therapies that
include the first new mechanisms of action for glaucoma treatment in nearly 20
years.

The Company’s lead product candidate, AR-12286, is a highly selective Rho
Kinase inhibitor that is the first glaucoma therapy to reduce intraocular
pressure by relaxing and clearing the trabecular meshwork, which is the eye’s
main fluid drain. AR-12286 is expected to be the new, convenient second-line
glaucoma drug of choice, in a market where nearly half of patients require
second-line or add-on therapy. Aerie’s PG286 fixed combination with travoprost
is the first glaucoma therapy to lower intraocular pressure by opening both of
the eye’s fluid drains. This new second-line therapy offers the convenience of
two drugs in one eye drop and the highest efficacy of any single drop glaucoma
medication. The Company’s third product, AR-13324, is a potential first line
therapy and the first of a new dual action drug class that reduces the eye’s
fluid inflow while also increasing fluid outflow through the trabecular
meshwork drain, all in a highly effective single drop per day.

Aerie is located in Bedminster, New Jersey and Research Triangle Park, North
Carolina. Further information on the Company is available at
www.aeriepharma.com.

Contact:

Aerie Pharmaceuticals
Thomas van Haarlem
President and Chief Executive Officer
(908) 470-4320
or
Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals
Justin Jackson
jjackson@burnsmc.com
(212) 213-0006
 
Press spacebar to pause and continue. Press esc to stop.